218 related articles for article (PubMed ID: 2568175)
1. Phase I and pharmacodynamic study of taxol in refractory acute leukemias.
Rowinsky EK; Burke PJ; Karp JE; Tucker RW; Ettinger DS; Donehower RC
Cancer Res; 1989 Aug; 49(16):4640-7. PubMed ID: 2568175
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of taxol given as a 3-hour infusion every 21 days.
Kris MG; O'Connell JP; Gralla RJ; Wertheim MS; Parente RM; Schiff PB; Young CW
Cancer Treat Rep; 1986 May; 70(5):605-7. PubMed ID: 2871928
[TBL] [Abstract][Full Text] [Related]
3. A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.
Rowinsky EK; Kaufmann SH; Baker SD; Miller CB; Sartorius SE; Bowling MK; Chen TL; Donehower RC; Gore SD
Clin Cancer Res; 1996 Dec; 2(12):1921-30. PubMed ID: 9816150
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
O'Brien S; Benvenuto JA; Estey E; Beran M; Felder TB; Keating M
Cancer Res; 1991 Feb; 51(3):935-8. PubMed ID: 1988134
[TBL] [Abstract][Full Text] [Related]
5. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical and pharmacokinetic study of taxol.
Wiernik PH; Schwartz EL; Strauman JJ; Dutcher JP; Lipton RB; Paietta E
Cancer Res; 1987 May; 47(9):2486-93. PubMed ID: 2882837
[TBL] [Abstract][Full Text] [Related]
7. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of taxol in patients with advanced cancer.
Donehower RC; Rowinsky EK; Grochow LB; Longnecker SM; Ettinger DS
Cancer Treat Rep; 1987 Dec; 71(12):1171-7. PubMed ID: 2891441
[TBL] [Abstract][Full Text] [Related]
9. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
[TBL] [Abstract][Full Text] [Related]
10. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of taxol administered as a short i.v. infusion daily for 5 days.
Grem JL; Tutsch KD; Simon KJ; Alberti DB; Willson JK; Tormey DC; Swaminathan S; Trump DL
Cancer Treat Rep; 1987 Dec; 71(12):1179-84. PubMed ID: 2891442
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor.
Schiller JH; Storer B; Tutsch K; Arzoomanian R; Alberti D; Feierabend C; Spriggs D
Semin Oncol; 1994 Oct; 21(5 Suppl 8):9-14. PubMed ID: 7524159
[TBL] [Abstract][Full Text] [Related]
13. Preliminary results of a phase I study of weekly paclitaxel infusion in patients with non-small cell lung cancer.
Akerley W; Glantz M; Choy H
Semin Oncol; 1996 Oct; 23(5 Suppl 12):14-8. PubMed ID: 8941405
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
Ibrahim NK; Desai N; Legha S; Soon-Shiong P; Theriault RL; Rivera E; Esmaeli B; Ring SE; Bedikian A; Hortobagyi GN; Ellerhorst JA
Clin Cancer Res; 2002 May; 8(5):1038-44. PubMed ID: 12006516
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
16. Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer.
Shepherd FA; Latreille J; Paul K; Eisenhauer E
Semin Oncol; 1996 Dec; 23(6 Suppl 16):84-90. PubMed ID: 9007130
[TBL] [Abstract][Full Text] [Related]
17. Sequences of taxol and cisplatin: a phase I and pharmacologic study.
Rowinsky EK; Gilbert MR; McGuire WP; Noe DA; Grochow LB; Forastiere AA; Ettinger DS; Lubejko BG; Clark B; Sartorius SE
J Clin Oncol; 1991 Sep; 9(9):1692-703. PubMed ID: 1678780
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer.
Tan CT; Hancock CH; Mondora A; Hoffman NW
Cancer Res; 1984 Feb; 44(2):831-5. PubMed ID: 6692381
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
Stevenson JP; Rosen M; Sun W; Gallagher M; Haller DG; Vaughn D; Giantonio B; Zimmer R; Petros WP; Stratford M; Chaplin D; Young SL; Schnall M; O'Dwyer PJ
J Clin Oncol; 2003 Dec; 21(23):4428-38. PubMed ID: 14645433
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
